GlassScriptPhysician profile
Clayton V Chan
NPI 1346340239
$1,865.95
in general payments reported to CMS, 2019-2025
28 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $18.15 · 2022: $89.32 · 2023: $287 · 2024: $987 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,548.49 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.58 | 2020-2025 | Imfinzi, Enhertu |
| Pfizer INC. | $253.81 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $153.21 | 2022-2025 | |
| Blueprint Medicines Corporation | $121.84 | 2024 | |
| Abbvie INC. | $109.12 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $104.11 | 2024 | Ingrezza |
| Aveo Pharmaceuticals, INC. | $99.99 | 2024 | |
| Coherus Oncology, INC. | $84.70 | 2024-2025 | Loqtorzi |
| Regeneron Healthcare Solutions, INC. | $66.16 | 2023-2024 | Libtayo |
| Lilly USA, LLC | $56.11 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Daiichi Sankyo INC. | $51.83 | 2025 | Datroway, Vanflyta |
| Incyte Corporation | $50.03 | 2023-2024 | Jakafi |
| Jazz Pharmaceuticals INC. | $39.48 | 2024 | |
| Beigene USA, INC. | $36.62 | 2023-2024 | Brukinsa |
| Astellas Pharma US INC | $33.97 | 2023-2024 | Xtandi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.75 | 2023-2024 | Tecentriq, Alecensa, Gavreto |
| Eusa Pharma (US) LLC | $30.62 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.01 | 2023 | Gilotrif |
| Adc Therapeutics America, INC. | $28.10 | 2022 | |
| Eisai INC. | $27.17 | 2023 | |
| Novo Nordisk INC | $24.88 | 2024 | |
| Karyopharm Therapeutics INC. | $24.88 | 2024 | Xpovio |
| Taiho Oncology, INC. | $24.62 | 2024 | |
| Caris Mpi, INC. | $23.97 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $21.45 | 2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $16.65 | 2023 | Ninlaro |
| Gilead Sciences, INC. | $14.80 | 2024 | |
| Janssen Biotech, INC. | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clayton Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.